Similarly, PI3K inhibitors, which are expected to reduce mTORC1 activity, acted synergistically with CDK4/6 inhibitors in models of mesothelioma and K-Ras-mutated non-small cell lung cancer (NSCLC) [126,127]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.